• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Lysophospholipid receptor nomenclature review: IUPHAR Review 8.溶血磷脂受体命名综述:IUPHAR综述8。
Br J Pharmacol. 2014 Aug;171(15):3575-94. doi: 10.1111/bph.12678. Epub 2014 Jul 12.
2
International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.国际基础和临床药理学联合会. LXXVIII. 溶血磷脂受体命名.
Pharmacol Rev. 2010 Dec;62(4):579-87. doi: 10.1124/pr.110.003111.
3
International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature.国际药理学联合会。三十四。溶血磷脂受体命名法。
Pharmacol Rev. 2002 Jun;54(2):265-9. doi: 10.1124/pr.54.2.265.
4
'Crystal' Clear? Lysophospholipid Receptor Structure Insights and Controversies.“水晶”般清晰?溶血磷脂受体结构的新见解和争议
Trends Pharmacol Sci. 2018 Nov;39(11):953-966. doi: 10.1016/j.tips.2018.08.006.
5
Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism.溶血磷脂受体:信号传导、药理学及溶血磷脂代谢的调节
Biochim Biophys Acta. 2007 Apr;1768(4):923-40. doi: 10.1016/j.bbamem.2006.09.026. Epub 2006 Oct 4.
6
Insights into the pharmacological relevance of lysophospholipid receptors.解析溶血磷脂受体的药理学相关性。
Br J Pharmacol. 2012 Feb;165(4):829-44. doi: 10.1111/j.1476-5381.2011.01622.x.
7
Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.溶血磷脂酸 G 蛋白偶联受体的药理学工具:LPA 和 S1P 受体激动剂和拮抗剂的开发。
Acta Pharmacol Sin. 2010 Sep;31(9):1213-22. doi: 10.1038/aps.2010.135. Epub 2010 Aug 23.
8
Lysophospholipids and their receptors in the central nervous system.中枢神经系统中的溶血磷脂及其受体
Biochim Biophys Acta. 2013 Jan;1831(1):20-32. doi: 10.1016/j.bbalip.2012.07.015. Epub 2012 Jul 31.
9
A short guide to the nomenclature of seven-transmembrane spanning receptors for lipid mediators.脂质介质七跨膜受体命名简指南。
Life Sci. 2005 Aug 19;77(14):1522-30. doi: 10.1016/j.lfs.2005.05.003.
10
Biological effects of lysophospholipids.溶血磷脂的生物学效应。
Rev Physiol Biochem Pharmacol. 2008;160:25-46. doi: 10.1007/112_0507.

引用本文的文献

1
Unraveling the Role of Autotaxin and Lysophosphatidic Acid in Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Potential.解析自分泌运动因子和溶血磷脂酸在阿尔茨海默病中的作用:从分子机制到治疗潜力
Int J Mol Sci. 2025 Jul 23;26(15):7068. doi: 10.3390/ijms26157068.
2
Neuroinflammation in an optimized model of lysophosphatidic acid (LPA)-induced post-hemorrhagic hydrocephalus.溶血磷脂酸(LPA)诱导的出血后脑积水优化模型中的神经炎症
Res Sq. 2025 Jun 3:rs.3.rs-6762718. doi: 10.21203/rs.3.rs-6762718/v1.
3
Lysophosphatidic acid 2 alleviates deep vein thrombosis via protective endothelial barrier function.溶血磷脂酸2通过保护内皮屏障功能减轻深静脉血栓形成。
Open Med (Wars). 2025 Feb 6;20(1):20241137. doi: 10.1515/med-2024-1137. eCollection 2025.
4
Unique pharmacological properties of etrasimod among S1P receptor modulators.依曲莫德在S1P受体调节剂中具有独特的药理学特性。
FEBS Open Bio. 2025 Jan;15(1):108-121. doi: 10.1002/2211-5463.13907. Epub 2024 Nov 20.
5
Structural mechanisms of potent lysophosphatidic acid receptor 1 activation by nonlipid basic agonists.非脂类碱性激动剂激活强效溶血磷脂酸受体 1 的结构机制。
Commun Biol. 2024 Nov 6;7(1):1444. doi: 10.1038/s42003-024-07152-y.
6
Pre-existing parasympathetic dominance seems to cause persistent heart rate slowing after 6 months of fingolimod treatment in patients with multiple sclerosis.在多发性硬化症患者中,预先存在的副交感神经优势似乎会导致在接受芬戈莫德治疗6个月后心率持续减慢。
Clin Auton Res. 2025 Feb;35(1):59-73. doi: 10.1007/s10286-024-01073-w. Epub 2024 Oct 9.
7
Sphingosine-1-phosphate receptor type 4 is critically involved in the regulation of peritoneal B-1 cell trafficking and distribution in vivo.1-磷酸鞘氨醇4型受体在体内对腹膜B-1细胞的运输和分布调节中起关键作用。
Eur J Immunol. 2024 Dec;54(12):e2350882. doi: 10.1002/eji.202350882. Epub 2024 Sep 29.
8
Targeting SNAI1-Mediated Colorectal Cancer Chemoresistance and Stemness by Sphingosine Kinase 2 Inhibition.通过抑制鞘氨醇激酶2靶向SNAI1介导的结直肠癌化疗耐药性和干性
World J Oncol. 2024 Oct;15(5):744-757. doi: 10.14740/wjon1890. Epub 2024 Sep 16.
9
Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials.S1PR调节剂etrasimod在诱导期治疗中度至重度活动性溃疡性结肠炎中的疗效和安全性:一项随机对照试验的系统评价和荟萃分析
Front Pharmacol. 2024 Sep 9;15:1420455. doi: 10.3389/fphar.2024.1420455. eCollection 2024.
10
Deciphering the role of sphingosine 1-phosphate in central nervous system myelination and repair.解读1-磷酸鞘氨醇在中枢神经系统髓鞘形成和修复中的作用。
J Neurochem. 2025 Jan;169(1):e16228. doi: 10.1111/jnc.16228. Epub 2024 Sep 17.

本文引用的文献

1
The Concise Guide to PHARMACOLOGY 2013/14: enzymes.《2013/14药理学简明指南:酶类》
Br J Pharmacol. 2013 Dec;170(8):1797-867. doi: 10.1111/bph.12451.
2
The Concise Guide to PHARMACOLOGY 2013/14: transporters.《2013/14药理学简明指南:转运体》
Br J Pharmacol. 2013 Dec;170(8):1706-96. doi: 10.1111/bph.12450.
3
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.《2013/14药理学简明指南:G蛋白偶联受体》
Br J Pharmacol. 2013 Dec;170(8):1459-581. doi: 10.1111/bph.12445.
4
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands.国际药理学联合会/英国药理学学会药物靶点和配体百科全书:一个由专家驱动的药物靶点和配体知识库。
Nucleic Acids Res. 2014 Jan;42(Database issue):D1098-106. doi: 10.1093/nar/gkt1143. Epub 2013 Nov 14.
5
Upregulation of GPR34 expression affects the progression and prognosis of human gastric adenocarcinoma by PI3K/PDK1/AKT pathway.GPR34 表达上调通过 PI3K/PDK1/AKT 通路影响人胃腺癌的进展和预后。
Histol Histopathol. 2013 Dec;28(12):1629-38. doi: 10.14670/HH-28.1629. Epub 2013 Jul 9.
6
International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands.国际基础和临床药理学联合会. LXXXVIII. G 蛋白偶联受体清单:与同源配体配对的建议。
Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. Print 2013 Jul.
7
Robust evidence for five new Graves' disease risk loci from a staged genome-wide association analysis.Graves 病风险 5 个新位点的稳健证据来自分阶段全基因组关联分析。
Hum Mol Genet. 2013 Aug 15;22(16):3347-62. doi: 10.1093/hmg/ddt183. Epub 2013 Apr 23.
8
Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D.鞘氨醇-1-磷酸介导的破骨细胞前体细胞单核细胞迁移是活性维生素 D 抗骨吸收作用的关键控制点。
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):7009-13. doi: 10.1073/pnas.1218799110. Epub 2013 Apr 8.
9
Sphingolipids in lung endothelial biology and regulation of vascular integrity.鞘脂在肺内皮生物学及血管完整性调节中的作用
Handb Exp Pharmacol. 2013(216):201-26. doi: 10.1007/978-3-7091-1511-4_10.
10
Sphingosine-1-phosphate and its receptors: structure, signaling, and influence.鞘氨醇-1-磷酸及其受体:结构、信号转导及影响。
Annu Rev Biochem. 2013;82:637-62. doi: 10.1146/annurev-biochem-062411-130916. Epub 2013 Mar 18.

溶血磷脂受体命名综述:IUPHAR综述8。

Lysophospholipid receptor nomenclature review: IUPHAR Review 8.

作者信息

Kihara Yasuyuki, Maceyka Michael, Spiegel Sarah, Chun Jerold

机构信息

Molecular and Cellular Neuroscience Department, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA, USA.

出版信息

Br J Pharmacol. 2014 Aug;171(15):3575-94. doi: 10.1111/bph.12678. Epub 2014 Jul 12.

DOI:10.1111/bph.12678
PMID:24602016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4128058/
Abstract

Lysophospholipids encompass a diverse range of small, membrane-derived phospholipids that act as extracellular signals. The signalling properties are mediated by 7-transmembrane GPCRs, constituent members of which have continued to be identified after their initial discovery in the mid-1990s. Here we briefly review this class of receptors, with a particular emphasis on their protein and gene nomenclatures that reflect their cognate ligands. There are six lysophospholipid receptors that interact with lysophosphatidic acid (LPA): protein names LPA1 - LPA6 and italicized gene names LPAR1-LPAR6 (human) and Lpar1-Lpar6 (non-human). There are five sphingosine 1-phosphate (S1P) receptors: protein names S1P1 -S1P5 and italicized gene names S1PR1-S1PR5 (human) and S1pr1-S1pr5 (non-human). Recent additions to the lysophospholipid receptor family have resulted in the proposed names for a lysophosphatidyl inositol (LPI) receptor - protein name LPI1 and gene name LPIR1 (human) and Lpir1 (non-human) - and three lysophosphatidyl serine receptors - protein names LyPS1 , LyPS2 , LyPS3 and gene names LYPSR1-LYPSR3 (human) and Lypsr1-Lypsr3 (non-human) along with a variant form that does not appear to exist in humans that is provisionally named LyPS2L . This nomenclature incorporates previous recommendations from the International Union of Basic and Clinical Pharmacology, the Human Genome Organization, the Gene Nomenclature Committee, and the Mouse Genome Informatix.

摘要

溶血磷脂包括多种源自细胞膜的小磷脂,它们作为细胞外信号发挥作用。其信号传导特性由7次跨膜G蛋白偶联受体(GPCR)介导,自20世纪90年代中期首次发现以来,该受体家族的成员不断被鉴定出来。在此,我们简要回顾这一类受体,特别强调其蛋白质和基因命名法,这些命名法反映了它们的同源配体。有六种与溶血磷脂酸(LPA)相互作用的溶血磷脂受体:蛋白质名称为LPA1 - LPA6,基因名称为斜体的LPAR1-LPAR6(人类)和Lpar1-Lpar6(非人类)。有五种1-磷酸鞘氨醇(S1P)受体:蛋白质名称为S1P1 - S1P5,基因名称为斜体的S1PR1-S1PR5(人类)和S1pr1-S1pr5(非人类)。溶血磷脂受体家族最近新增的成员包括:一种溶血磷脂酰肌醇(LPI)受体的暂定名称——蛋白质名称为LPI1,基因名称为LPIR1(人类)和Lpir1(非人类);以及三种溶血磷脂酰丝氨酸受体——蛋白质名称为LyPS1、LyPS2、LyPS3,基因名称为LYPSR1-LYPSR3(人类)和Lypsr1-Lypsr3(非人类),还有一种在人类中似乎不存在的变体形式,暂定为LyPS2L。这种命名法纳入了国际基础与临床药理学联合会、人类基因组组织、基因命名委员会和小鼠基因组信息学先前的建议。